Clinical Features and Structured Clinical Evaluation of Vasculitis
Overview
Authors
Affiliations
Systemic vasculitides are a group of heterogeneous conditions with overlapping patterns of clinical and laboratory manifestations. Moreover, clinical features can be non-specific and seemingly disparate. A major factor in defining optimal therapy and measuring treatment response is careful disease assessment targeting four main domains: activity, damage, prognosis and quality of life/function. Assessment tools such as the Birmingham Activity Score and the Vasculitis Damage Index have become a core feature of clinical trials in ANCA-associated vasculitis (AAV) and formed the basis for sound clinical management of these complex conditions. We are still lacking accurate definitions of disease activity and damage progression in large-vessel vasculitis. There is an increasing interest in the role of patient-reported outcomes as a measure of disease impact; a disease-specific measure for use in AAV is being validated. We review how best to evaluate patients with large-, medium- and small-vessel vasculitis.
A Spectacular Effect of Tocilizumab in Takayasu Arteritis.
Said F, Naceur I, Ben Achour T, Jridi M, Smiti M Eur J Case Rep Intern Med. 2024; 11(12):004868.
PMID: 39651392 PMC: 11623354. DOI: 10.12890/2024_004868.
Cardiovascular pathology in vasculitis.
De Gaspari M, Ascione A, Baldovini C, Marzullo A, Pucci A, Rizzo S Pathologica. 2024; 116(2):78-92.
PMID: 38767541 PMC: 11138763. DOI: 10.32074/1591-951X-993.
Wen R, Xiao J, Ding N, Zhong Y, Yuan Q, Li J Eur J Clin Microbiol Infect Dis. 2024; 43(6):1061-1072.
PMID: 38536523 DOI: 10.1007/s10096-024-04807-w.
Nienhuis P, van Nieuwland M, van Praagh G, Markusiewicz K, Colin E, van der Geest K Diagnostics (Basel). 2024; 14(1).
PMID: 38201371 PMC: 10802840. DOI: 10.3390/diagnostics14010062.
Granath A, Pettersson S, Gunnarsson I, Welin E, Dahlberg K Rheumatol Adv Pract. 2023; 7(3):rkad092.
PMID: 37954916 PMC: 10637867. DOI: 10.1093/rap/rkad092.